Literature DB >> 15150082

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

Jun Yuan1, David B Lovejoy, Des R Richardson.   

Abstract

Aroylhydrazone and thiosemicarbazone iron (Fe) chelators have potent antitumor activity. The aim of the current study was to examine the antitumor effects and mechanisms of action of a novel series of Fe chelators, the di-2-pyridyl thiosemicarbazones. Of 7 new chelators synthesized, 4 showed pronounced antiproliferative effects. The most active chelator was Dp44mT, which had marked and selective antitumor activity-for example, an IC(50) of 0.03 microM in neuroepithelioma cells compared with more than 25 microM in mortal fibroblasts. Indeed, this antiproliferative activity was the greatest yet observed for an Fe chelator. Efficacy was greater than it was for the cytotoxic ligand 311 and comparable to that of the antitumor agent doxorubicin. Strikingly, Dp44mT significantly (P <.01) decreased tumor weight in mice to 47% of the weight in the control after only 5 days, whereas there was no marked change in animal weight or hematologic indices. Terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) staining demonstrated apoptosis in tumors taken from mice treated with Dp44mT. This chelator caused a marked increase of caspase-3 activity in murine Madison-109 (M109) cells. Caspase activation was at least partially mediated by the release of mitochondrial holo-cytochrome c (h-cytc) after incubation with Dp44mT. In conclusion, Dp44mT is a novel, highly effective antitumor agent in vitro and in vivo that induces apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150082     DOI: 10.1182/blood-2004-03-0868

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  98 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

3.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).

Authors:  Patric J Jansson; Tetsuo Yamagishi; Akanksha Arvind; Nicole Seebacher; Elaine Gutierrez; Alexandra Stacy; Sanaz Maleki; Danae Sharp; Sumit Sahni; Des R Richardson
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

Review 4.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

5.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), an anticancer agent, exerts an anti-inflammatory effect in activated human mast cells.

Authors:  Sun-Young Nam; Na-Ra Han; Kyoung Wan Yoon; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Inflamm Res       Date:  2017-06-14       Impact factor: 4.575

6.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.

Authors:  V Ashutosh Rao; Sarah R Klein; Keli K Agama; Eriko Toyoda; Noritaka Adachi; Yves Pommier; Emily B Shacter
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  IRP2 regulates breast tumor growth.

Authors:  Wei Wang; Zhiyong Deng; Heather Hatcher; Lance D Miller; Xiumin Di; Lia Tesfay; Guangchao Sui; Ralph B D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

8.  Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest.

Authors:  Fan Zhang; Wei Wang; Yoshiaki Tsuji; Suzy V Torti; Frank M Torti
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

9.  Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai.

Authors:  Amber B Moore; Jackilen Shannon; Chu Chen; Johanna W Lampe; Roberta M Ray; Sharon K Lewis; Minggang Lin; Helge Stalsberg; David B Thomas
Journal:  Int J Cancer       Date:  2009-09-01       Impact factor: 7.396

Review 10.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.